Plasma Circulating Terminal Differentiation–Induced Non-Coding RNA Serves as a Biomarker in Breast Cancer

Breast cancer is identified as the most common malignancy and cause of cancer-related death worldwide. Compared with healthy controls, this study evaluated the expression level and diagnostic power of lncRNA plasma TINCR in breast cancer patients.

Fifty-eight women diagnosed with invasive ductal carcinoma and fifty healthy age-matched controls were included in the study. TRIzol® LS regent was used to isolate the total RNA from the whole plasma. Total RNA was converted to cDNA using Prime ScriptTM RT reagent kit and the expression levels of TINCR were quantified by qRT-PCR.

Low levels of TINCR lncRNA were observed in the plasma of breast cancer patients compared with control subjects. Plasma TINCR level was also positively correlated with the diagnostic age of breast cancer patients.

A low level of plasma TINCR could discriminate breast cancer patients from healthy control subjects.